Goldman Sees Hot Weather in Asia Moderating LNG Flows to Europe
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Biochip Market Global Outlook Report 2025, with Focus on Microarrays and Lab-on-a-Chip
Discover comprehensive insights into the global biochip market, providing revenue analysis, trends, and forecasts to 2029. Examine segmented data by product type, technology, application, and region, and explore sustainability, ESG developments, and key players like Abbott and Agilent Technologies. Global Biochip Market Market Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Biochip Market: Microarrays and Lab-on-a-Chip" report has been added to global market for biochip was valued at $16.1 billion in 2024 and is estimated to reach $27.8 billion by 2029, at a compound annual growth rate (CAGR) of 11.6% from 2024 through global biochip market is witnessing significant growth, driven by the increasing demand for rapid and accurate diagnostic solutions, advances in genomics and proteomics, and the rising adoption of personalized medicine. Biochips, which combine several biochemical assays onto a miniaturized platform, are transforming disciplines like drug discovery, disease diagnosis and biomarker studies. Microarrays and lab-on-a-chip technology allow high-throughput screening, allowing researchers and clinicians to analyze biological samples more quickly and increasing incidence of infectious and chronic diseases and point-of-care testing needs drive biochip use in hospitals, pharmaceutical firms and research centers. Technological advances in nanotechnology, microfluidics and biosensors also improve biochip performance, making them more sensitive, cost-effective and scalable. With government initiatives and increased R&D investments in biotechnology and healthcare, the market is poised for substantial expansion in coming years. Comprehensive market sizing and forecasting will enable stakeholders to identify high-growth segments and regions, understand competitive dynamics and make informed decisions for strategic planning during the forecast period. The report focuses on the significant trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses patents and emerging technologies related to the report concludes with an analysis of the competitive landscape, which provides the ranking and shares of key companies in the global biochip market. There is also a dedicated section on company profiles that provides details about leading companies in the company profiles offer detailed information about business segments, financials, product portfolios and recent developments. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, with estimates for 2024 and a forecast for 2025 through Scope 76 data tables and 56 additional tables An analysis of the current and future global markets for biochip diagnostic products and technologies Analyses of global market trends, with historic revenue data from 2021 to 2024, and projected CAGRs through 2029 Estimates of the size of and revenue prospects for the global biochip market, along with a market share analysis by product type, technology, application, end-user vertical, and region Facts and figures pertaining to the market dynamics, technological advances, regulations, and the impact of macro-economic factors A look at the major commercial biochip products and the future potential of each key market segment, emerging technologies, clinical trials, and other new developments Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading biotech companies Analysis of the industry structure, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Company profiles of major players within the industry, including Abbott, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., and BioMerieux Key Attributes: Report Attribute Details No. of Pages 136 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $16.1 Billion Forecasted Market Value (USD) by 2029 $27.8 Billion Compound Annual Growth Rate 11.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview and Market Definition Technology Background Technological Infrastructure and Data Integration Chapter 3 Market Dynamics Market Drivers Rising Demand for Point-of-Care Diagnostics Increasing Investment and Funding in Biochip and Microarray Research Activities Increasing Prevalence of Cancer Generating Demand for Personalized Treatments Market Restraints and Challenges High Costs Associated with Developing and Implementing Biochip Technology Technical Challenges Market Opportunities Technological Advances and Automation in the Biochip industry Growing Volume of Clinical Research Chapter 4 Regulatory Landscape Market Regulations by Agency The U.S. Federal Regulation CMS Regulation FDA Regulation FTC Regulation Canada European Union The U.K. China Japan Australia International Standards and Guidelines Chapter 5 Emerging Technologies and Developments Artificial Intelligence in Biochip Technology for Biomedicine Advances in DNA and Protein Microarrays 3D Microarrays and Organoid-on-a-Chip Hydrogel-Based Microarrays Other Types of 3D Microarrays Chapter 6 Market Segmentation Analysis Global Biochip Market by Product Microarrays (Array-Based Biochips) Microfluidic Biochips (Lab-on-a-Chip) Biochip Equipment and Software Biochip Consumables and Kits Global Biochip Market by Technology Microarray Technology Microfluidics Technology Global Biochip Market by Application Genomics Proteomics Disease Diagnostics Drug Discovery and Development Global Biochip Market by End User Academic and Research Institutes Biopharmaceutical Companies Hospitals and Diagnostic Centers Geographic Breakdown Global Biochip Market by Region Market Size and Forecast North America Europe Asia-Pacific Rest of World (ROW) Chapter 7 Competitive Intelligence Industry Structure Breakthrough Technologies and Product Launches Top Company Rankings Key Strategies Adopted by Companies Collaborations and Partnerships New Product Launch Expansion and Investment Mergers and Acquisitions Chapter 8 Sustainability in the Biochip Market: An ESG Perspective Introduction to ESG ESG Performance in the Biochip Market ESG Practices in the Biochip Industry Environmental Performance Social Performance Governance Performance ESG Risk Ratings Company Profiles Abbott Agilent Technologies Inc. Biomerieux Bio-Rad Laboratories Inc. F. Hoffmann-La Roche Ltd. Ibiochips Illumina Inc. Li-Cor Biotech Micronit Nutcracker Therapeutics Inc. Qiagen Randox Laboratories Ltd. Revvity Standard Biotools Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Global Biochip Market Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Growth in municipal water investment steady but industry takes a hit amid US tariff uncertainty
OXFORD, United Kingdom, July 17, 2025 (GLOBE NEWSWIRE) -- The latest global water market forecast from Global Water Intelligence (GWI) extends projections to 2030, expecting global capital expenditure on water infrastructure to grow at a 3.8% 5-year CAGR despite the shock from United States trade tariffs. New data from GWI shows that despite uncertainty over the tariffs imposed by the US administration, urgent global drivers like water security concerns, regulation and ageing infrastructure mean utility spending has remained relatively insulated, with more impacts being felt in industrial water spending. GWI anticipates that heavy industries like chemicals manufacturing, refining & petrochemicals and other industrial manufacturing (including steel and automotives) are likely to be most negatively impacted by the global economic uncertainty, with a reduced water spending outlook as a result. However, the buildout of data centres to support AI is translating into growing water-related spending in related industries such as power generation. GWI has revised its forecast to account for higher growth in water capital expenditure for power generation in key data centre markets such as the US. Meanwhile, a combination of regulatory pressure, increasing water stress concerns and a rush to use EU money as a funding cycle ends is expected to see Europe's utility capital expenditure growth to 2030 outpace that of North America and East Asia/Pacific. The Middle East and Africa and Latin America are also expected to see solid growth on the back of water and wastewater treatment buildouts to expand service provision and address water scarcity. GWI forecasts are updated quarterly and are broken out by CAPEX vs OPEX, region, country, application, sector & technology. Access full forecast data dashboards or book a demo directly at For general enquiries contact sales@ About Global Water Intelligence Global Water Intelligence (GWI) is the leading market intelligence and events company serving the international water industry. Over the last 25 years we have built our business around being a trusted interface between our clients and their markets, providing our customers with high-level intelligence that enables them to make the most informed strategic decisions for their business. We cover municipal markets and every industrial vertical as well as technology, finance, and economics. CONTACT: Malin HedlundCOMPANY: Global Water IntelligencePHONE: 01865 204208 EMAIL: sales@ in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Coface SA: Coface agrees to acquire Novertur International SA (business-monitor.ch), enhancing its Business Information offer in Switzerland
Coface agrees to acquire Novertur International SA ( enhancing its Business Information offer in Switzerland Paris, 17 July 2025 – 18.30 Coface announces the signing of an agreement to acquire 100% of Novertur International SA. Novertur International SA, a Swiss startup based in Lausanne, has developed strong digital expertise in managing data on Swiss companies, which it distributes through its platform Launched in 2016, the platform has become a key tool for SMEs and large companies in Switzerland for risk management and B2B prospecting. It offers simple, fast and reliable access to up-to-date information on more than 730,000 active Swiss businesses. The technological innovations developed by Novertur International SA - particularly in data structuring and user experience - combined with Coface's expertise in credit risk, will significantly strengthen Coface's Business Information offering in Switzerland. This acquisition strengthens the Group's data, technical capabilities and expertise, in full alignment with its strategic plan Power the Core, which aims to enhance its high value-added services while strengthening its local presence. Florent Schlaeppi, CEO and Founder of commented: 'From day one, we designed to be intuitive, fast, and useful for anyone analyzing companies. Joining Coface is a tremendous opportunity to take our mission to the next level by putting our technology at the service of a global player in business risk.' Christian Moins, Country Manager Coface Switzerland, commented: 'We are particularly excited to welcome the Business Monitor team to Coface. The acquisition of Business Monitor demonstrates Coface's ambition to establish itself as a key player in Business Information. This transaction significantly strengthens our position in the Swiss market, making Coface an even more attractive partner for its clients. ' The completion of the acquisition remains subject to the usual closing conditions. CONTACTS ANALYSTS / INVESTORSThomas JACQUET: +33 1 49 02 12 58 – Rina ANDRIAMIADANTSOA: +33 1 49 02 15 85 – MEDIA RELATIONSSaphia GAOUAOUI: +33 1 49 02 14 91 – BILLET: +33 1 49 02 23 63 – FINANCIAL CALENDAR 2025(subject to change)H1-2025 results: 31 July 2025 (after market close) 9M-2025 results: 3 November 2025 (after market close) FINANCIAL INFORMATIONThis press release, as well as COFACE SA's integral regulatory information, can be found on the Group's website: For regulated information on Alternative Performance Measures (APM), please refer to our Interim Financial Report for H1-2024 and our 2024 Universal Registration Document (see part 3.7 'Key financial performance indicators'). Regulated documents posted by COFACE SA have been secured and authenticated with the blockchain technology by can check the authenticity on the website COFACE: FOR TRADEAs a global leading player in trade credit risk management for more than 75 years, Coface helps companies grow and navigate in an uncertain and volatile environment. Whatever their size, location or sector, Coface provides 100,000 clients across some 200 markets with a full range of solutions: Trade Credit Insurance, Business Information, Debt Collection, Single Risk insurance, Surety Bonds, day, Coface leverages its unique expertise and cutting-edge technology to make trade happen, in both domestic and export markets. In 2024, Coface employed ~5,236 people and registered a turnover of €1.84 billion. COFACE SA is quoted in Compartment A of Euronext ParisCode ISIN: FR0010667147 / Ticker: COFA DISCLAIMER - Certain declarations featured in this press release may contain forecasts that notably relate to future events, trends, projects or targets. By nature, these forecasts include identified or unidentified risks and uncertainties, and may be affected by many factors likely to give rise to a significant discrepancy between the real results and those stated in these declarations. Please refer to chapter 5 'Main risk factors and their management within the Group' of the Coface Group's 2024 Universal Registration Document filed with AMF on 3 April 2025 under the number D.25-0227 in order to obtain a description of certain major factors, risks and uncertainties likely to influence the Coface Group's businesses. The Coface Group disclaims any intention or obligation to publish an update of these forecasts, or provide new information on future events or any other circumstance. Attachment 2025 07 17 PR Novertur acquisition agreement
